Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768079 | 0.87 | HRH3 (0.84) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL29808986 | 0.83 | GRIN2D (0.47) | HRH3AOC3KDM4ELOXL2 | |
| SCHEMBL23070463 | 0.83 | GRIN2D (0.47) | HRH3AOC3KDM4ELOXL2 | |
| SCHEMBL13078725 | 0.82 | HRH3 (0.69) | HRH3MAPT | |
| SCHEMBL6224751 | 0.82 | HRH3 (0.61) | HRH3HDAC8HDAC6KDM4ELOXL2 | |
| SCHEMBL7315530 | 0.81 | HRH3 (0.50) | HRH3HDAC8HDAC6AOC3 | |
| SCHEMBL1638551 | 0.81 | HRH3 (0.52) | HRH3MAPT | |
| SCHEMBL1813157 | 0.81 | HRH3 (0.67) | HRH3HDAC8HDAC6PYCR1LOXL2 | |
| SCHEMBL12680476 | 0.80 | HRH3 (1.00) | HRH3HDAC8HDAC6AOC3PYCR1 | |
| SCHEMBL5926009 | 0.80 | HRH3 (0.73) | HRH3HDAC8HDAC6PYCR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| US-11078195-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2021-08-03 | — | — | US | disclosed |
| US-20210171513-A1 | NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2021-06-10 | — | — | US | disclosed |
| WO-2021042410-A1 | SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110627767-B | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-08-25 | — | — | CN | disclosed |
| US-20200247795-A1 | NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2020-08-06 | — | — | US | disclosed |
| CN-110627767-A | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
| CN-1438890-A | Adenosine receptor modulators | HOFFMANNLA ROCHE AG F (CH) | 2003-08-27 | — | — | CN | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| US-6030984-A | 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5869500-A | INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998025930-A2 | USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-18 | — | — | WO | disclosed |
| US-4507510-A | Process for producing xylyleneglycol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078195-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | HRH3 3649/4885HDAC8 265/4885HDAC6 123/4885 |
| US-20200247795-A1 | NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME | NAMPT, NAPRT, NNMT | HRH3 3817/4885HDAC8 296/4885HDAC6 144/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | HRH3 131/4885HDAC8 1783/4885HDAC6 1816/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | HRH3 1412/4885HDAC8 4685/4885HDAC6 4178/4885 |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | HRH3 1353/4885HDAC8 1852/4885HDAC6 302/4885 |
| US-20210171513-A1 | NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME | NAMPT, NAPRT, NNMT | HRH3 3817/4885HDAC8 296/4885HDAC6 144/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | HRH3 1253/4885HDAC8 1940/4885HDAC6 346/4885 |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | HRH3 3649/4885HDAC8 265/4885HDAC6 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.